Inhaled Molgramostim Therapy in Autoimmune Pulmonary Alveolar Proteinosis

In this RCT of 138 pts, daily use of continuous inhaled molgramostim resulted in greater improvements in pulmonary gas transfer vs placebo at week 24 (baseline change in alveolar–arterial difference in oxygen conc; −12.8 vs −6.6 mm Hg; treatment difference, −6.2 mm Hg; p=0.03).

SPS commentary:

Molgramostim is an investigational recombinant human granulocyte macrophage colony stimulating factor that is administered via inhalation.


New England Journal of Medicine